AR042472A1 - Preparaciones de liberacion controlada que comprenden tramadol y topiramato - Google Patents

Preparaciones de liberacion controlada que comprenden tramadol y topiramato

Info

Publication number
AR042472A1
AR042472A1 ARP030104634A ARP030104634A AR042472A1 AR 042472 A1 AR042472 A1 AR 042472A1 AR P030104634 A ARP030104634 A AR P030104634A AR P030104634 A ARP030104634 A AR P030104634A AR 042472 A1 AR042472 A1 AR 042472A1
Authority
AR
Argentina
Prior art keywords
hours
tramadol
preparation
substrate
effective amount
Prior art date
Application number
ARP030104634A
Other languages
English (en)
Original Assignee
Cilag Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cilag Ag filed Critical Cilag Ag
Publication of AR042472A1 publication Critical patent/AR042472A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Preparación farmacéutica oral adecuada para la dosificación cada 24 horas, que comprende un sustrato, en donde el sustrato comprende una cantidad farmacéuticamente eficaz de tramadol o una sal de dicho compuesto y una cantidad farmacéuticamente eficaz de topiramato, y en donde dicho sustrato puede estar revestido con un revestimiento de liberación controlada; dicha preparación tiene una proporción de disolución específica in vitro. Reivindicación 1: Una preparación farmacéutica oral de liberación controlada adecuada para la dosificación cada 24 horas, que comprende un sustrato que contiene una cantidad farmacéuticamente eficaz de tramadol o una sal de dicho compuesto y una cantidad farmacéuticamente eficaz de topiramato; dicha preparación tiene una proporción de disolución in vitro medida usando el Método de Paleta de la Ph. Eur.(Ph. Eur. Paddle Method) a 75 rmp en 900 ml de buffer de fosfato 0,05 M a 37sC y utilizando HPLC: entre 15 y 35% de tramadol liberado después de 1 hora; entre 28 y 48% de tramadol liberado después de 2 horas; entre 47 y 67% de tramadol liberado después de 4 horas; entre 68 y 88% de tramadol liberado después de 8 horas; entre 79 y 99% de tramadol liberado después de 12 horas; entre 86 y 105% de tramadol liberado después de 24 horas; en peso, en donde dicha preparación suministra un efecto terapéutico durante aproximadamente 24 horas luego de la administración oral. Reivindicación 17: Un proceso para la elaboración de una preparación farmacéutica oral según se reivindica en las reivindicaciones 1 a 16, que comprende mezclar clorhidrato de tramadol y topiramato con un sustrato adecuado.
ARP030104634A 2002-12-13 2003-12-15 Preparaciones de liberacion controlada que comprenden tramadol y topiramato AR042472A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02080325 2002-12-13
EP03075123 2003-01-10

Publications (1)

Publication Number Publication Date
AR042472A1 true AR042472A1 (es) 2005-06-22

Family

ID=32598791

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030104634A AR042472A1 (es) 2002-12-13 2003-12-15 Preparaciones de liberacion controlada que comprenden tramadol y topiramato

Country Status (15)

Country Link
US (1) US20060147527A1 (es)
EP (1) EP1572192A1 (es)
JP (1) JP2006514986A (es)
KR (1) KR20050075408A (es)
AR (1) AR042472A1 (es)
AU (1) AU2003296672A1 (es)
BR (1) BR0317177A (es)
CA (1) CA2506807A1 (es)
CL (1) CL2003002621A1 (es)
MX (1) MXPA05006210A (es)
MY (1) MY148475A (es)
PL (1) PL377351A1 (es)
RU (1) RU2005122008A (es)
TW (1) TW200427448A (es)
WO (1) WO2004054571A1 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US7790905B2 (en) 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
EP1494998A2 (en) 2002-03-01 2005-01-12 University Of South Florida Multiple-component solid phases containing at least one active pharmaceutical ingredient
CA2489984A1 (en) 2002-06-21 2003-12-31 Transform Pharmaceuticals, Inc. Pharmaceutical compositions with improved dissolution
US8183290B2 (en) 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
EP2316456B1 (en) 2003-04-29 2017-06-14 Orexigen Therapeutics, Inc. Compositions for affecting weight loss comprising an opioid antagonist and bupropion
CA2572928A1 (en) 2004-07-22 2006-02-26 Amorepacific Corporation Sustained-release preparations containing topiramate and the producing method thereof
CN101068538A (zh) 2004-11-04 2007-11-07 什诺波特有限公司 加巴喷丁前体药物持续释放口服剂型
WO2007025233A1 (en) 2005-08-26 2007-03-01 Regents Of The University Of Minnesota Decellularization and recellularization of organs and tissues
MXPA05011735A (es) * 2005-11-01 2007-04-30 Leopoldo Espinosa Abdala Composiciones farmaceuticas que comprenden combinaciones de analgesicos y anticonvulsivantes para el tratamiento del dolor agudo y cronico.
WO2007067341A2 (en) 2005-11-22 2007-06-14 Orexigen Therapeutics, Inc. Compositions and methods for increasing insulin sensitivity
US20190083399A9 (en) * 2006-04-03 2019-03-21 Isa Odidi Drug delivery composition
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
US9744137B2 (en) * 2006-08-31 2017-08-29 Supernus Pharmaceuticals, Inc. Topiramate compositions and methods of enhancing its bioavailability
KR101479324B1 (ko) * 2006-11-09 2015-01-05 오렉시젠 세러퓨틱스 인크. 신속하게 용해되는 중간층을 포함하는 층상의 약제학적 제형
MX343867B (es) 2006-11-09 2016-11-25 Orexigen Therapeutics Inc Paquete de dosificacion unitaria y metodos para administrar medicaciones de perdida de peso.
WO2008061226A2 (en) 2006-11-17 2008-05-22 Supernus Pharmaceuticals Inc. Sustained-release formulations of topiramate
CN102218044A (zh) * 2006-12-04 2011-10-19 苏佩努斯制药公司 托吡酯的增强的立即释放制剂
DE102007026550A1 (de) * 2007-06-08 2008-12-11 Bayer Healthcare Ag Extrudate mit verbesserter Geschmacksmaskierung
CA2725930A1 (en) 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
US20100003322A1 (en) * 2008-07-03 2010-01-07 Lai Felix S Enteric coated hydrophobic matrix formulation
DK2328561T3 (en) * 2008-08-19 2016-02-08 Adcock Ingram Intellectual Property Pty Ltd Rate modulated administration of drugs from a three-layered tablet containing tramadol, diclofenac, paracetamol
JP5783908B2 (ja) 2008-12-19 2015-09-24 スパーナス ファーマシューティカルズ インコーポレイテッド 攻撃性を治療する方法
US9248123B2 (en) 2010-01-11 2016-02-02 Orexigen Therapeutics, Inc. Methods of providing weight loss therapy in patients with major depression
WO2011123497A1 (en) 2010-03-31 2011-10-06 Supernus Pharmaceuticals Inc. Stabilized formulations of cns compounds
CN103458935B (zh) 2010-09-01 2016-08-03 明尼苏达大学董事会 使组织或器官再细胞化以提高其可移植性的方法
US10702485B2 (en) 2011-07-09 2020-07-07 Syntrix Biosystems Inc. Compositions and methods for overcoming resistance to tramadol
AU2013271622B2 (en) 2012-06-06 2018-03-01 Nalpropion Pharmaceuticals Llc Methods of treating overweight and obesity
US9290738B2 (en) 2012-06-13 2016-03-22 Miromatrix Medical Inc. Methods of decellularizing bone
US8652527B1 (en) * 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
WO2014151739A1 (en) 2013-03-15 2014-09-25 Miromatrix Medical Inc. Use of perfusion decellularized liver for islet cell recellularization
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
US11278643B2 (en) 2016-09-06 2022-03-22 Mayo Foundation For Medical Education And Research Use of resected liver serum for whole liver-engineering
US11000488B2 (en) 2019-03-22 2021-05-11 Syntrix Biosystems Inc. Treating pain using desmetramadol

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3652589A (en) * 1967-07-27 1972-03-28 Gruenenthal Chemie 1-(m-substituted phenyl)-2-aminomethyl cyclohexanols
US4513006A (en) * 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
GB8601204D0 (en) * 1986-01-18 1986-02-19 Boots Co Plc Therapeutic agents
JPH0474515A (ja) * 1990-07-13 1992-03-09 Toray Ind Inc 酸素吸収体
ES2120451T7 (es) * 1991-09-06 2009-11-05 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Composicion que comprende un compuesto de tramadol y acetaminofeno, y su uso.
MX9205106A (es) * 1991-09-06 1993-05-01 Johnson & Johnson Composiciones que comprenden un material de tramadol y cualquiera de codeina, oxicodona o hidrocodona y su uso
US5516803A (en) * 1991-10-30 1996-05-14 Mcneilab, Inc. Composition comprising a tramadol material and a non-steroidal anti-inflammatory drug
US5292534A (en) * 1992-03-25 1994-03-08 Valentine Enterprises, Inc. Sustained release composition and method utilizing xanthan gum and an active ingredient
IL109460A (en) * 1993-05-10 1998-03-10 Euro Celtique Sa Controlled release formulation comprising tramadol
GB9710699D0 (en) * 1997-05-24 1997-07-16 Danbiosyst Uk Gastro-retentive controlled release system
US5760007A (en) * 1997-07-16 1998-06-02 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating neuropathic pain
MXPA02001820A (es) * 1999-08-20 2003-07-14 Johnson & Johnson Composicion que comprende un material de tramadol y un farmaco anticonvulsivo.
EP1508595B1 (en) * 2001-10-25 2010-02-17 Asahi Kasei Chemicals Corporation Polyphenylene sulfide resin composition
EP1364649A1 (en) * 2002-05-23 2003-11-26 Cilag AG Adduct of topiramate and tramadol hydrochioride and uses thereof

Also Published As

Publication number Publication date
MY148475A (en) 2013-04-30
BR0317177A (pt) 2005-10-25
CA2506807A1 (en) 2004-07-01
RU2005122008A (ru) 2006-02-10
US20060147527A1 (en) 2006-07-06
JP2006514986A (ja) 2006-05-18
KR20050075408A (ko) 2005-07-20
PL377351A1 (pl) 2006-01-23
MXPA05006210A (es) 2005-08-19
EP1572192A1 (en) 2005-09-14
CL2003002621A1 (es) 2005-03-11
TW200427448A (en) 2004-12-16
AU2003296672A1 (en) 2004-07-09
WO2004054571A1 (en) 2004-07-01

Similar Documents

Publication Publication Date Title
AR042472A1 (es) Preparaciones de liberacion controlada que comprenden tramadol y topiramato
RU2005115855A (ru) Композиция трамадола продлонгированного высвобождением с 24-часовым действием
RS50056B (sr) Kompozicije oksikodona sa kontrolisanim oslobađanjem
EA200700049A1 (ru) Препаративные формы оральных лекарственных форм мемантина с модифицированным высвобождением
DK293087A (da) Fast dihydrocodeinpraeparat med reguleret afgivelse
DE3773468D1 (de) Hydromorphon-zusammensetzung mit gesteuerter wirkstofffreisetzung.
BR0008590A (pt) Agente de entrega polimérico, composição, formade unidade de dosagem, método para administrarum agente biologicamente ativo a um animalnecessitando o agente, método para preparar umacomposição; e composto
AR028504A2 (es) Combinacion, metodo para mejorar la apariencia corporal de un mamifero, composicion farmaceutica, uso de dicha combinacion para la preparacion de un medicamento para la prevencion, demora de progreso, o tratamiento de desordenes metabolicos, y paquete comercial
BR9510168A (pt) Composto poliaminoácido composição forma unitária de dosagem e método par epreparar uma composição
AR085778A2 (es) Forma de dosis solida enterica revestida, que comprende acido micofenolico o sal micofenolato
RS52577B (en) ONE-DAY OXYCODON FORMULATIONS
BR0214757A (pt) Formulações farmacêuticas de derivados de platina
ATE424810T1 (de) Ein hydrokolloid und einen celluloseether enthaltende tablette mit verzögerter freisetzung
HN1999000183A (es) Preparado farmaceuticos de moxifloxacina
PE20021017A1 (es) Composicion parenteral reconstituible
ECSP066318A (es) Composición para la liberación de una base debil por un periodo extendido de tiempo
ES2168241T1 (es) Preparacion farmaceutica que contiene tolperisona para administrar por via oral.
HUP0004780A2 (hu) Prosztaglandin agonisták felhasználása merevedési rendellenességek vagy impotencia kezelésében
AR043536A1 (es) Composicion farmaceutica que comprende acido 5-metil-2-(2´-cloro-6´-fluoroanilino)fenilacetico
BR9911756A (pt) Composto, uso de um secretagogo do hormÈnio do crescimento ou um seu sal farmaceuticamente aceitável, composição farmacêutica, método para estimular a liberação do hormÈnio do crescimento pela pituitária de um mamìfero, e, uso de um composto
RS50058B (sr) Kompozicije oksikodona sa kontrolisanim oslobađanjem
PE20011042A1 (es) Uso de glutamina para la prevencion de diarrea de inicio tardio inducida por irinotecan
YU20050409A (sh) Kompozicije oksikodona sa kontrolisanim oslobađanjem
BR0312333A (pt) Terapia de combinação e agente para sua execução
AR017240A2 (es) COMPOSICIONES DE ÁCIDO ALENDRoNICO , SUS SALES O ESTERES

Legal Events

Date Code Title Description
FA Abandonment or withdrawal